Ovidiu Negrea, MD
Medical Oncology · Savannah, GANPI 1457319931
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Veracyte, Inc. at 33.2% of the total. Reporting peaked in 2022 at $1,822 and has fallen 89.1% since, to $198 in 2025. That places this record below the midpoint for medical oncology clinicians in GA, where the typical reported total is $5,509.
Across 31 payments — averaging $96.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veracyte, Inc.$994
- Johnson & Johnson$742
- Novartis$315
- AstraZeneca$242
- Adaptive Biotechnologies Corporation$189
- Gilead$152
- plus $356 from 10 others
Across 8 payments — averaging $17,214 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$88K
- AbbVie$50K
What the payments were for
- Consulting fees$68323%
- Speaking & faculty fees$90030%
- Food & beverage$1,07336%
- Education$361%
- Other$29910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veracyte, Inc. | 2 | $994 |
| Johnson & Johnson | 3 | $742 |
| Novartis | 4 | $315 |
| AstraZeneca | 2 | $242 |
| Adaptive Biotechnologies Corporation | 3 | $189 |
| Gilead(2 entities) | 3 | $152 |
| Seagen Inc. | 3 | $135 |
| Sanofi | 2 | $57 |
| Tempus AI, Inc | 2 | $33 |
| Bayer | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| GE HealthCare | 1 | $18 |
| Immunogen, Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
| Tesaro, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,990 in reported general payments places this provider in the 35th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 149 | $2,768,769 |
| BrukinsaZanubrutinib | 102 | $1,475,603 |
| CabometyxCabozantinib S-Malate | 48 | $1,140,692 |
| IbrancePalbociclib | 60 | $912,498 |
| PomalystPomalidomide | 38 | $808,093 |
| JakafiRuxolitinib Phosphate | 44 | $725,164 |
| Lenalidomide | 47 | $684,865 |
| XtandiEnzalutamide | 30 | $409,144 |
| ImbruvicaIbrutinib | 18 | $380,541 |
| TukysaTucatinib | 12 | $288,553 |
| VenclextaVenetoclax | 27 | $255,931 |
| NinlaroIxazomib Citrate | 19 | $240,209 |
| TagrissoOsimertinib Mesylate | 13 | $192,101 |
| Abiraterone Acetate | 80 | $158,966 |
| Somatuline DepotLanreotide Acetate | 17 | $154,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $24 | $409,14430 claims |
| Seagen Inc.Tukysa | $135 | $288,55312 claims |
| AstraZenecaTagrisso | $242 | $192,10113 claims |
| Johnson & JohnsonXarelto | $742 | $47,59244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Savannah
- Haven Caldwell-SacharSavannah$3K
- Samir KhleifAugusta$337K
- Nabil SabaAtlanta$225K
- Sreekanth ReddyVidalia$116K
- Hagop YoussoufianDecatur$78K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.